Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: An open-label trial

World Journal of Biological Psychiatry

Volumn 10, Issue 2, 2009, Pages 156-162

  Chung, Young Chul ^a   Lee, Chun Rong ^a   Park, Tae Won ^a   Yang, Keum Hwa ^a   Kim, Ki Won ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Atypical antipsychotics; Cognition; Donepezil; Schizophrenia

Indexed keywords

AMISULPRIDE; BENZATROPINE; CLOZAPINE; DONEPEZIL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZOTEPINE; INDAN DERIVATIVE; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

ADULT; ANOREXIA; ARTICLE; ATTENTION; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DIARRHEA; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; MEMORY; NAUSEA; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOMOTOR ACTIVITY; RATING SCALE; SCHIZOPHRENIA; DOSE RESPONSE; DRUG COMBINATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 67649406776     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701432551     Document Type: Article

References (39)

1. Addington J, Addington D, Gasbarre L. 2001. Neurocognitive and social functioning in schizophrenia and other diagnoses. Schizophr Res 48:367-368. (Pubitemid 32274333)
2. Buchanan RW, Davis M, Goff D, Green MF, Keefe RSE, Leon AC, et al. 2005. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 31:5-19.
3. Buchanan RW, Summerfelt A, Tek C, Gold J. 2002. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 59:29-33.
4. Bryson GJ, Silverstein ML, Nathan A, Stephen L. 1993. Differential rate of neuropsychological dysfunction in psychiatric disorders: Comparison between the Halstead-Reitan and Luria-Nebraska batteries. Percept Mot Skills 76:305-306.
5. Cannon TD, Eyler-Zorrilla L, Shtasel D, Gur RC, Marco EJ, Moberg P, et al. 1994. Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry 51:651-661.
6. Carpenter WT, Gold JM. 2002. Another view of therapy for cognition in schizophrenia. Biol Psychiatry 51:969-971.
7. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. 2000. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48:381-388.
8. Cummings J, Goman D, Shapira J. 1993. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 33:536-541.
9. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. 1999. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 156:1328-1335.
10. Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA. 2005. Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol 28:179-184.
11. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL. 2002. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51:349-357.
12. Freedman R, Hall M, Adler LE, Leonard S. 1995. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38: 22-33.
13. Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC, Cather C, et al. 2005. Added donepezil for stable schizophrenia: a double-blind placebo-controlled trial. Psycho-pharmacology 181:358-363.
14. Green MF, Kern RS, Braff DL, Mintz J. 2000. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophr Bull 26:119-136.
15. Green MF, Nuechterlein KH, Breitmeyer B. 1997. Backward masking performance in unaffected siblings of schizophrenia patients: evidence for a vulnerability indicator. Arch Gen Psychiatry 54:465-472
16. Guy W 1976. Assessment manual for Psychopharmacology. Rockville: National Institute of Mental Health. Harvey PD, Keefe RSE. 2001. Studies of the cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158:176-184.
17. Harvey PD, Palmer BW, Heaton RK, Mohamed S, Kennedy J, Brickman A. 2005. Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study. Am J Psychiatry 162:110-117.
18. Ichikawa J, Dai J, O'Laughlin A, Fowler WL, Meltzer HY. 2002. Atypical, but not typical antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26:325-339.
19. Karson CN, Mrak RE, Husain MM, Griffin WS. 1996. Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions. Mol Chem Neuropathol 29:181-191.
20. Kay SR. 1991. Positive and Negative Syndromes in Schizophrenia. New York: Brunner/Mazel.
21. Keefe RSE, Poe M, Walker TM, Kang JW, Harvey PD. 2006. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry 163:426-432 (Pubitemid 44469384)
22. Kwon JS, Lyoo IK, Hong KS, Yeon BK, Ha KS. 2002. Development and standardization of the computerized memory assessment for Korean adults. J Korean Neuropsychiatr Assoc 41:347-358.
23. Lee BJ, Lee JG, Kim YH. 2006. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloper-idol for treating cognitive impairments in patients with chronic schizophrenia. J Psychopharmacol (ahead of print)
24. Lezak MD. 1995. Neuropsychological Assessment. 3r Edn. New York: Oxford University Press.
25. Liang Y, Tang X. 2006. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmacologica Sinica 27(9):1127-1136.
26. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. 2005. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 62:361-370.
27. Mazeh D, Zemishlani H, Barak Y, Mirecki I, Paleacu D. 2005. Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. Int Psychogeriatrics 1-8.
28. McKeith I, Del Ser T, Spano PF, Emre M, Wesnes K, Anand R, et al. 2000. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 356:2031-2036.
29. Mitchell IJ, Cooper AC, Griffiths MR, Cooper AJ. 2002. Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. Neuroscience 109:89-99.
30. Nahas Z, George MS, Horner MD, Markowitz JS, Li X, Lorberbaum JP, et al. 2003. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase 9:274-282.
31. Palmer BW, Heaton RK, Paulsen JS, Kuck J, Braff D, Harris MJ, et al. 1997. Is it possible to be schizophrenic yet neuropsycho-logically normal? Neuropsychology 11:437-446.
32. Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, David SR, et al. 2000. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57:249-258.
33. Reyes JF, Preskorn SH, Khan A, Kumar D, Cullen EL, Perdomo CA, et al. 2004. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol 58:50-57.
34. Schilstrom B, Ivanov VB, Wiker C, Svensson TH. 2007. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 32:43-53.
35. Schubert MH, Young KA, Hicks PB. 2006. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 60:530-533.
36. Tugal O, Yazici KM, Yagcioglu AEA, Gogus A. 2004. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 7:117-123.
37. Wyatt RJ. 1986. The dopamine hypothesis: variations on a theme (II). Psychopharmacol Bull 22:923-927.
38. Wyatt RJ. 1991. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17:325-351.
39. Zhao Q, Xie C, Pesco-Koplowitz L, Jia X, Parier JL. 2003. Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil. J Clin Pharmacol 43:180-186.